Podcasts about AML

Happy 2023, as well as a happy Chinese New Year of the Rabbit. 2023 Chris and Joe will again bring you startup news once a month (with a small summer break) wrapping up what was going on — and we found noteworthy — in the GSA / DACH startups scene.Our Highlights:WeFox is under fire for growing with acquisitions of insurance broker pools, BioNTech makes largest acquisition in its history, DeepL confirms unicorn status and snipes at Grammarly, Solarisbank in trouble with BaFin, Trade Republic has to disclose numbers and Sono Motors gets longer runway with EU money.Let's talk startups:Subscribe HereFind all options to subscribe to our newsletter, podcast, YouTube channel or listen to our internet radio station here: https://linktr.ee/startupradioOur EnablersInvest-in-HessenThis show was made possible by Hessen Trade and Invest with their brand Invest-in-Hessen. You can learn more about them here (https://www.invest-in-hessen.com/). We also run a dedicated sub-podcast with all interviews and news in cooperation with them. Look for Tech Startups Germany here: https://linktr.ee/startupradioStartupraven.comThe best way to identify investors and cooperation partners for early-stage startups. Sign up for early access here: Startup RavenTop NewsWeFox got some splaining to do

It is true that times have changed, but the industry hasn't done itself any favors recently when it comes to its reputation. Concerning the fabric of financial services, things are never that straightforward. The last year has demonstrated that there has indeed been fraud, manipulation and illegal activity involving crypto, although not directly related to crypto. So what is next in the complicated web of financial integrity and national security?On this episode of “Money Reimagined,” while Michael Casey is in Davos, Switzerland, host Sheila Warren speaks with two of the foremost experts on this topic, Dr. Marcus Pleyer, the former president of the Financial Action Task Force and now the deputy director general of Germany's Federal Ministry of Finance; and Yaya Fanusie, director of policy for AML and cyber risk at the Crypto Council for Innovation and an Adjunct Senior Fellow at the Center for a New American Security (CNAS).-This episode was produced and edited by Michele Musso with announcements by Adam B. Levine and our executive producer, Jared Schwartz. Our theme song is “Shepard.”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

It is true that times have changed, but the industry hasn't done itself any favors recently when it comes to its reputation. Concerning the fabric of financial services, things are never that straightforward. The last year has demonstrated that there has indeed been fraud, manipulation and illegal activity involving crypto, although not directly related to crypto. So what is next in the complicated web of financial integrity and national security?On this episode of “Money Reimagined,” while Michael Casey is in Davos, Switzerland, host Sheila Warren speaks with two of the foremost experts on this topic, Dr. Marcus Pleyer, the former president of the Financial Action Task Force and now the deputy director general of Germany's Federal Ministry of Finance; and Yaya Fanusie, director of policy for AML and cyber risk at the Crypto Council for Innovation and an Adjunct Senior Fellow at the Center for a New American Security (CNAS).-This episode was produced and edited by Michele Musso with announcements by Adam B. Levine and our executive producer, Jared Schwartz. Our theme song is “Shepard.”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In January 2022, Dr. Amir Fathi, Associate Professor of Medicine at Harvard Medical School, served as faculty for Therapy of B-Cell Acute Lymphoblastic Leukemia (ALL): an Evolving Landscape, presented during the ODACon Rare Hematologic Malignancies Symposium. Recently, numerous significant updates in both ALL and acute myeloid leukemia (AML) were presented at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans. In this interview, Dr. Fathi elaborates on these exciting developments in the ever-changing treatment landscape for acute leukemia. Click here to view and claim credit for Therapy of B-Cell Acute Lymphoblastic Leukemia: an Evolving Landscape, an accredited CME/NCPD/CPE activity provided by i3 Health: https://i3health.com/odacon-all

In this week's episode we'll discuss the benefits of allogeneic hematopoietic stem cell transplantation in older and medically infirm patients with AML, learn more about the efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents, and review the role of anti-CD20 therapy in relapsed immune-mediated thrombotic thrombocytopenic purpura.

cc: growth journeys from emerging ecosystems to global markets. (Episode in English - live recording during cc: Nights in Tallinn) Taavi Tamkivi is the founder & CEO of the Salv, which is an AML platform built by the creators of TransferWise & Skype's compliance. Salv gives companies the flexibility and speed they need to get ahead of financial criminals. Gelecek etkinliklerimizden haberdar olmak için bültenimize abone olun: https://www.getcced.com/#CTA You can reach us through our website ( getcced.com ) or @getcced on Instagram, Twitter, Youtube, Facebook, and Linkedin. Hosted by Enis Hulli, Rina Onur and Arin Ozkula.

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia — Faculty Presentation 2: Treatment of AML with Targetable Mutations — Dr Andrew Wei CME information and select publications

Featuring perspectives from Drs Courtney DiNardo and Mark Levis, including the following topics: Introduction (0:00) Case: A man in his early 80s with newly diagnosed acute myeloid leukemia (AML) with significant comorbidities receives decitabine/venetoclax — Rebecca L Olin, MD, MSCE (7:36) Cases: A man in his mid 50s after 7 + 3 and allogeneic stem cell transplantation (SCT) presents with myeloid sarcoma; a man in his late 70s after 7 + 3 and allogeneic SCT presents with myeloid sarcoma — Spencer H Bachow, MD and Ranju Gupta, MD (12:16) Case: A man in his late 30s with core binding factor AML after induction CLAG-M with gemtuzumab ozogamicin followed by high-dose cytarabine x 4 — Anna Halpern, MD (18:10) Case: A woman in her mid 60s with newly diagnosed del(5q) AML with monocytic differentiation and multiple mutations (GATA2, BCOR, NF1 and RUNX1) receives azacitidine and venetoclax — Bhavana (Tina) Bhatnagar, DO (31:05) Selection of Therapy for Patients with AML (35:20) Cases: A man in his early 50s with therapy-related AML with an MLL mutation who receives CPX-351; a man in his early 70s with secondary AML with an IDH mutation — Amany R Keruakous, MD, MS and Priya Rudolph, MD, PhD (41:42) Case: A man in his early 70s with recurrent AML with an IDH2 mutation receives enasidenib and develops differentiation syndrome/disease progression — Dr Halpern (50:00) CME information and select publications

In this week's episode, we'll discuss new research revealing that the mechanosensory ion channel Piezo1 is the elusive carrier molecule of the Er blood group antigens, thus establishing a new blood group system. Next, we review results of a randomized phase 3 trial of enasidenib versus conventional treatment in late-stage mutant-IDH2 relapsed or refractory AML. Although the primary endpoint of overall survival was not met, investigators say the risk benefit ratio remains positive. Finally, we'll review a study showing a clinically significant risk of breakthrough COVID-19 infections in patients with B-cell malignancies despite vaccination and pre-exposure prophylaxis with tixagevimab-cilgavimab during the Omicron era. However, hospitalization rates in the study were low and no deaths were reported.

The best tool FINRA provides when it comes to firms developing their annual compliance program is now available. The 2023 Report on FINRA's Examination and Risk Monitoring Program provides key insights and observations on two dozen key regulatory topics, making it a must-read for compliance professionals. On this episode, Ornella Bergeron, Senior Vice President of Risk Monitoring, Michael Solomon, Senior Vice President of Examinations, and Bill St. Louis, Executive Vice President of the National Cause and Financial Crimes Detection Programs (NCFC), join us to dig into some of the new and noteworthy topics in the latest report. Resources mentioned in this episode:2023 Report on FINRA's Examination and Risk Monitoring ProgramEpisode 112: Introducing FINRA's Complex Investigations and Intelligence Team and Cyber and Analytics UnitEpisode 71: Overlapping Risks, Part 1: Anti-Money Laundering and Cybersecurity

Anti-Money Laundering Professional William “Bill” Callahan joined Veronica LIVE to discuss cryptocurrency, SBF, fraud and so much more. He recently was named Linked In's 20 most influential professionals in the world of anti-money laundering. Check out his inverview with Veronica.

Over the last few years, federal regulators have provided detailed guidance on what they expect to see in E&C programs when it comes to misconduct inquiries or investigations. What do these recent reports, policies, and guidance mean for compliance professionals? In this episode of the Principled Podcast, LRN Director of Thought Leadership and Best Practices Susan Divers is joined by Jon Drimmer, a partner at the law firm Paul Hastings. Listen in as the two discuss the recent guidance from the US Department of Justice as well as DOJ policy impacting corporate compliance programs and ethical culture.  To learn more, download the 2022 Ethics & Compliance Program Effectiveness Report.   Guest: Jon Drimmer Jonathan C. Drimmer is a partner in the Investigations and White Collar Defense practice and is based in the Washington, D.C. office of Paul Hastings. He resolves complex cross-border problems with the benefit of having sat in every chair at the table: senior legal officer for a global 500 company, federal prosecutor, and seasoned advocate. He is a recognized international expert on anti­corruption and business and human rights, and is a frequent speaker, author, and commentator on issues related to both topics. Before joining Paul Hastings, he was Deputy General Counsel and Chief Compliance Officer of Barrick Gold, one of the world's largest mining companies, with operations on five continents. The compliance program he built at Barrick has served as an industry standard, and elements of it have largely been duplicated by numerous other companies inside and outside of the extractive sector. Mr. Drimmer has directed hundreds of investigations around the world related to anti-corruption, human rights, AML and export controls, tax controversies, environmental incidents, public disclosures, fatalities and health and safety injuries, sexual harassment and discrimination, and other areas. He has represented companies and individuals in numerous government enforcement proceedings in the U.S. and overseas, in relation to FCPA and bribery claims, human rights issues, and a wide array of other matters. He has participated in dozens of major disputes in the U.S., Canada, and abroad, including transnational torts, anti-corruption claims, environmental cases, international arbitrations, tax disputes, construction claims, and land controversies. He previously served in the Justice Department as Deputy Director of the Criminal Division's Office of Special Investigations, where he led cross-border investigations, first-chaired numerous prosecutions, and argued federal appeals. He was a partner at an Am Law 100 law firm in Washington, D.C., a former Bristow Fellow in the Office of the U.S. Solicitor General, and a judicial clerk on the U.S. Court of Appeals for the Ninth Circuit. Mr. Drimmer served on the board of directors of the Voluntary Principles on Security and Human Rights Initiative from 2012-2014, and again from 2015-2017. He served on the board of TRACE International from 2012 until 2018, and currently sits on the board of the TRACE Foundation. He has also taught international law courses at Georgetown University Law Center for nearly 20 years.   Host: Susan Divers Susan Divers is the director of thought leadership and best practices with LRN Corporation. She brings 30+ years' accomplishments and experience in the ethics and compliance arena to LRN clients and colleagues. This expertise includes building state-of-the-art compliance programs infused with values, designing user-friendly means of engaging and informing employees, fostering an embedded culture of compliance, and sharing substantial subject matter expertise in anti-corruption, export controls, sanctions, and other key areas of compliance. Prior to joining LRN, Mrs. Divers served as AECOM's Assistant General for Global Ethics & Compliance and Chief Ethics & Compliance Officer. Under her leadership, AECOM's ethics and compliance program garnered six external awards in recognition of its effectiveness and Mrs. Divers' thought leadership in the ethics field. In 2011, Mrs. Divers received the AECOM CEO Award of Excellence, which recognized her work in advancing the company's ethics and compliance program. Before joining AECOM, she worked at SAIC and Lockheed Martin in the international compliance area. Prior to that, she was a partner with the DC office of Sonnenschein, Nath & Rosenthal. She also spent four years in London and is qualified as a Solicitor to the High Court of England and Wales, practicing in the international arena with the law firms of Theodore Goddard & Co. and Herbert Smith & Co. She also served as an attorney in the Office of the Legal Advisor at the Department of State and was a member of the U.S. delegation to the UN working on the first anti-corruption multilateral treaty initiative.  Mrs. Divers is a member of the DC Bar and a graduate of Trinity College, Washington D.C. and of the National Law Center of George Washington University. In 2011, 2012, 2013 and 2014 Ethisphere Magazine listed her as one the “Attorneys Who Matter” in the ethics & compliance area. She is a member of the Advisory Boards of the Rutgers University Center for Ethical Behavior and served as a member of the Board of Directors for the Institute for Practical Training from 2005-2008. She resides in Northern Virginia and is a frequent speaker, writer and commentator on ethics and compliance topics.  For a transcript of this podcast, please visit the episode page at LRN.com.

In this week's episode we'll discuss whether pregnancy increases the risk of bleeding in women with immune thrombocytopenia, compare the outcomes of allogeneic stem cell transplantation versus conservative management in adults with inborn errors of immunity, and learn more about the long-term health outcomes and late mortality in childhood AML survivors.

Listen to a blog summary of a trending research paper published by Oncotarget: "Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model." _________________________________________________________ The average age of patients with acute myeloid leukemia (AML) is 67 years old. Older adults generally have a lower tolerance for treatments that exhibit high off-target toxicity. Additionally, chemotherapy-relapsed or -refractory (R/R) AML patients are often at an advanced stage of disease and are therefore more likely to have comorbidities that may reduce their tolerance for harsh treatments. Thus, pharmaceutical AML drugs with high efficacy and low toxicity are in high demand. Antibody drug conjugates (ADCs) are emerging as promising therapeutic approaches to more safely treat hematological malignancies by reducing side effects. ADCs are designed to decrease damage to healthy tissues by specifically targeting tumor-associated antigens attached to cancer cells. “Antibody drug conjugates (ADC) are one of the modalities that aims to dissociate drug efficacy from toxicity. ADC consists of three components: antibody specific for tumor associated antigen, drug linker and cytotoxic payload.” ASTELLAS PHARMA Recently, researchers from Astellas Pharma Inc. (a pharmaceutical company in Japan) developed ASP1235—a novel ADC that targets Fms-like tyrosine kinase 3 (FLT3). In more than 90% of AML patients, FLT3 is overexpressed on leukemic blasts. ASP1235 is designed to target FLT3-positive leukemia cells and deliver the cytotoxic drug payload to these cells. However, this drug alone was found to have only a mild effect on AML cells, prompting researchers to assess the efficacy of ASP1235 in combination with other drugs. In a new study, Astellas Pharma researchers Hirofumi Tsuzuki, Tatsuya Kawase, Taisuke Nakazawa, Masamichi Mori, and Taku Yoshida investigated the efficacy of ASP1235 combined with venetoclax (an anti-apoptotic agent) and azacitidine (a DNA methyltransferase inhibitor) in an experimental mouse model of AML. Their research paper was published in Oncotarget on December 20, 2022, and entitled, “Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model.” Full blog: https://www.oncotarget.org/2023/01/04/novel-antibody-drug-conjugate-improves-murine-acute-myeloid-leukemia/ DOI: https://doi.org/10.18632/oncotarget.28331 Corresponding author: Hirofumi Tsuzuki - hirofumi.tsuzuki@astellas.com Keywords: acute myeloid leukemia (AML), ASP1235, antibody drug conjugate (ADC), venetoclax, azacitidine About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/OncotargetYouTube LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Got a question for the trio? - https://zfrmz.com/uLtjhyBskV96PY6eJfaI https://propertyplanning.com.au/propertyplannerbuyerprofessor/ In this week's episode, Dave, Cate and Pete take you through: The difference between ROI (return on investment) and ROE (return on equity). Pete explains this critical differential and he and Dave highlight the sheer power of leveraging with a simple example. Our Property Professor shares some valuable formulae to consider in relation to the time value of money, including net present value (NPV). Gross lease vs net lease. Pete compares the differences and explains the critical things that commercial property landlords need to be familiar with when it comes to calculating and forecasting their rental returns. Finance terms: LVR, LMI, AML, VOI, valuation types (short form, long form, desktop, curbside, AVM, as if complete). Dave takes our listeners through each of these terms, some of which may be very familiar for our listeners but he has some twists and turns to shed light on for some of the lesser known acronyms and he expands on some of the detail behind many of these concepts. Valuation vs appraisal: why is this critical to understand? Even if the techniques are the the same, one is libel and one is just an opinion. Pete explores this important discretion. AIP (approval in principle), partial and full drawdowns, LOO. Dave covers these acronyms for our listeners and shares some great detail on construction lending; something particularly detailed for strategic mortgage brokers and banks, but a concept that many wouldn't necessarily know. COC and FTC : A certificate of currency (COC) is a requirement for every newly purchased property, and it's easy to arrange but often prompts a lot of questions. Funds to complete (FTC) is one of the most stressful last minute conversations when it's unexpected and raising a question around shortfall funds. Cate and Dave shed light on some of the causes of this so that our listeners can provision for the unexpected headache at settlement time. ...and our gold nuggets! "Don't change your job while you're going for a loan or awaiting settlement!" Peter Koulizos, the 'Property Professor's Gold Nugget: Pete suggests that any borrowers who find themselves confused about acronyms in their loan documentation or correspondence, they should ask their strategic mortgage broker or banker to explain it all. The team wish our listeners a happy 2023 with a special message each from the Property Planner, the Property Buyer and the Property Professor. Visit the show notes: https://propertyplanning.com.au/common-terms-and-acronyms-part-1-from-roi-to-voi-we-unpack-them-all-ep-186/

Sean Topchi joins Michael Rasile on For the Love of Sports to chat about his sports betting and gaming career. Sean grew up in Vegas, giving him a unique perspective on the industry he was constantly around. When others would come to visit for a weekend to live it up, it was just another day to Sean. He started his career with Caesars Entertainment where he climbed the corporate ladder from intern to managing a piece of their Antimoney laundering department. Sean currently works as the Director of Business Development from Kinectify, where they have an out-of-the-box solution to help sports betting, gaming, and igaming companies better tackle their AML problem.s https://www.linkedin.com/in/seantopchi/ https://www.kinectify.com/

In this week's episode, we'll discuss involvement of IL-13 and IL-4 signaling in fibrotic progression of myelofibrosis; next, we review results on a novel agent using vWF-dependent mechanisms to lyse pathological thrombi in acute ischemic stroke. Finally, we'll shed new light on findings that implicate the GARP-TGF-beta-1 pathway in the loss of natural killer cell cytotoxicity in relapsed AML.

It's the day after Christmas and for many of us around the globe it's known as Boxing Day, while for many others, it's simply known as Monday and while recovering from heaping mounds of turkey, bread stuffing and Aunt Emily's Christmas pudding at the AML Nation's world headquarters, we decided there was no need for a podcast on such a magical day. But wait, while some of the AML gang were cleaning up the studio after what can only be described as an epic Christmas party, someone hit the switch and microphones went live and we loaded up the recording on our trusty cassette player so everyone could hear what could only be described as our “Boxing Day a.k.a. Monday” podcast. Grab yourself a big bowl of shredded plastic bows, a tall cool glass of week-old tree water and enjoy!!

gm. Mauricio Magaldi and Cuy Sheffield are back this week for another deep dive. In this Insights episode, we will be focusing on AML and how regulation can be a solution. We explore how the industry is preventing money laundering and illicit financing, looking at recent developments and what we hope the future can bring in this sector. Join us while we unpack what AML is in traditional finance, and how it differs from AML in crypto, blockchains and digital assets, what's working and what's not, and of course - what we hope to see in the near future. We are also joined by some amazing guests: Ari Redbord, Head of Legal and Government Affairs at TRM Labs Jessica Cath, Head of Financial Crime Project Delivery, Fintrail This episode is sponsored by Visa. This episode is brought to you by Visa, one of the world's leaders in digital payments. Crypto has opened up a new world of possibility. And Visa is helping everyone take part. Visa enables commerce across their network and crypto networks through solutions like Fintech Fast Track, a quick and easy way for crypto innovators to issue payment credentials. Join us in this new money movement. Learn more at visa.com/crypto (https://partner.visa.com/homepage.html?utm_source=partner&utm_medium=affiliate&utm_content=sponsored-podcast_english_60min0sec&utm_campaign=us_fintech_q3-fy21-11fs-fintechinsider&utm_creative=awareness_11fs-fintech-insider). If you enjoyed the show, don't forget to subscribe and leave a review! Want to join the conversation on all the topics discussed? Tweet the show at: www.twitter.com/bchaininsider Special Guests: Ari Redbord and Jessica Cath.

A study using chimeric antigen receptor (CAR)-T cells has proven to be safe for treating patients with relapsed or refractory acute myeloid leukemia (AML). The agent known as PRGN-3006 also brought remissions among patients who had chemotherapy for lymphodepletion prior to their CAR-T cell procedure (Abstract 4633). After the lead author of the new study, David Sallman, MD, from the Moffitt Cancer Center in Tampa, Florida, had reported the new findings at the 2022 Annual Meeting of the American Society of Hematology, OncTimes Talk correspondent Peter Goodwin interviewed him about the study and about the overall prospects of using CAR-T cells to treat AML. PRGN-3006 UltraCAR-T is a multigenic autologous chimeric antigen receptor (CAR)-T simultaneously expressing a CAR specifically targeting CD33; membrane bound IL-15 (mbIL15) for enhanced in vivo expansion and persistence; and a kill switch to conditionally eliminate CAR-T cells for an improved safety profile. CD33 is over-expressed on AML blasts with lesser expression on normal hematopoietic stem cells. PRGN-3006 UltraCAR-T drug product is manufactured via an overnight process at medical centers using the Company's proprietary non-viral and UltraPorator systems and released for infusion in patients the next day. The decentralized, overnight UltraCAR-T manufacturing process, which does not use viral vectors or ex vivo activation and expansion of T cells, has the potential to address major limitations of current T cell therapies. PRGN-3006 UltraCAR-T has been granted Orphan Drug Designation and Fast Track Designation in patients with AML by the FDA. The Phase I/Ib clinical study is designed to enroll in two phases, an initial dose escalation phase followed by a dose expansion phase, to evaluate safety and determine the recommended Phase II dose of PRGN-3006 delivered via intravenous (IV) infusion without lymphodepletion (Cohort 1) or with lymphodepletion (Cohort 2). The study is also evaluating in vivo persistence and anti-tumor activity of PRGN-3006.

Acute myeloid leukemia (AML), also called acute myelogenous leukemia, is a cancer of the blood and bone marrow, the spongy tissue inside bones where blood cells are made. The disease progresses rapidly, affecting a group of white blood cells called myeloid cells, which normally develop into mature red blood cells, white blood cells and platelets. "There are acute and chronic leukemias, explains Dr. James Foran, an oncologist at Mayo Clinic. "The chronic ones tend to happen slowly over many years. You can watch it for a period of time until it really becomes active. The acute leukemias come on more quickly and cause people to get sick more quickly. Hence, the word acute."AML occurs when a bone marrow cell develops mutations in its DNA that cause the cell to continue growing and dividing. When this happens, blood cell production becomes out of control. The bone marrow produces immature cells that develop into leukemic white blood cells called myeloblasts. These abnormal cells are unable to function properly, and they can build up and crowd out healthy cells.Signs and symptoms of AML include: Fever Bone pain Lethargy and fatigue Shortness of breath Pale skin Frequent infections Easy bruising Unusual bleeding Treatment of acute myeloid leukemia depends on several factors, including the subtype of the disease, and a person's age and overall health. At the time of diagnosis, a bone marrow biopsy is performed, and testing is done to determine the subtype of AML. Genetic testing on leukemia cells helps oncologists plan treatment that will give patients the highest chance of remission."There have been massive advances in the last five or seven years," explains Dr. Foran. "We understand that almost everybody with acute myeloid leukemia will have some genetic abnormality in the leukemia cells. Some mutations predict for a lower remission rate with standard chemotherapies. Those are situations where we're looking for new therapies that would be more effective, new strategies — whether that's an immune treatment, a targeted therapy, a different type of chemotherapy. So those mutations really helped guide us on how to apply the new strategies." Dr. Foran says Mayo Clinic is a leader in ongoing research and clinical trials to refine and improve targeted and immune therapy treatments. New approaches include expanding the use of bone marrow transplants and using CAR-T cell therapy. "Mayo Clinic is in the front of the field, I believe. We're studying more targeted treatments to go after cells with mutations, to try to spare side effects, and get the most benefit in treating leukemia," he says. "We're continually and actively looking for new strategies to improve outcomes for patients."On this Mayo Clinic Q&A podcast, Dr. Foran discusses acute myeloid leukemia, including the latest research and advances in treatments.

As another year draws to a close it's time once again for our annual state of the hobby and with so much happening in the hobby, we here at the ole' AML world headquarters decided this would be the ideal time for the newest editor of Model Railroader magazine to share his thoughts about where this great hobby of ours is headed. Of course, such an interview wouldn't be complete without help from everybody's favorite “Uncle” Dave, who's always excited to talk all things railroading. Eric White is a veteran journalist with a wealth of model railroading knowledge behind him, he joined Model Railroader as an associate editor and looks forward to leading it into the future. Leading the hobby's flagship publication is an important role which Eric plans to take very seriously. He enjoys the operations side of the hobby and meeting readers of the magazine. This is great podcast and one we're sure you'll enjoy!!

Jared and Katie's "Breaking & Entering Christmas" happened again this morning! The surprised family was more deserving than ever. A mother and 3 daughters lost their father to cancer this year, and one of the daughters has had major health complications their whole life. Today was truly a day of joy and a blessing all around! Thank you to everyone who made it possible, including our sponsors and our loyal AML's who donated to the cause as well!See omnystudio.com/listener for privacy information.

Jared and Katie's "Breaking & Entering Christmas" happened again this morning! The surprised family was more deserving than ever. A mother and 3 daughters lost their father to cancer this year, and one of the daughters has had major health complications their whole life. Today was truly a day of joy and a blessing all around! Thank you to everyone who made it possible, including our sponsors and our loyal AML's who donated to the cause as well!See omnystudio.com/listener for privacy information.

Jared and Katie's "Breaking & Entering Christmas" happened again this morning! The surprised family was more deserving than ever. A mother and 3 daughters lost their father to cancer this year, and one of the daughters has had major health complications their whole life. Today was truly a day of joy and a blessing all around! Thank you to everyone who made it possible, including our sponsors and our loyal AML's who donated to the cause as well!See omnystudio.com/listener for privacy information.

Jared and Katie's "Breaking & Entering Christmas" happened again this morning! The surprised family was more deserving than ever. A mother and 3 daughters lost their father to cancer this year, and one of the daughters has had major health complications their whole life. Today was truly a day of joy and a blessing all around! Thank you to everyone who made it possible, including our sponsors and our loyal AML's who donated to the cause as well!See omnystudio.com/listener for privacy information.

Pre-show Banter SBF wasn't just a proponent of Effective Altruism, his career was defined by their philosophy (https://www.semafor.com/article/12/07/2022/charity-money-launched-sam-bankman-frieds-empire) News ECB staff threaten to strike over non-inflation adjusted wages (https://archive.ph/EXgSz) CFTC declares Etherium, Tether, and bitcoin (https://cointelegraph.com/news/cftc-declares-ether-as-a-commodity-again-in-court-filing) commodities in a bizzare aside in a legal complaint against FTX and SBF (Scam Bankrupt Fraud) This aside is likely necessary to establish CFTC jurisdiction (https://www.courtlistener.com/docket/66631227/1/commodity-futures-trading-commission-v-bankman-fried/) Belgium has surprising reasonable regulatory guidance (https://cointelegraph.com/news/belgium-says-btc-eth-and-other-decentralized-coins-are-not-securities) regarding crypto assets but fails to identify the obfuscated centralized control of Etherium U.S. Senator Elizabeth Warren's Digital Asset Anti-Money Laundering Act (warning government PDF) (https://www.warren.senate.gov/imo/media/doc/DAAML%20Act%20of%202022.pdf) seeks to define many individual participants in bitcoin as money transmiters (https://www.coincenter.org/the-digital-asset-anti-money-laundering-act-is-an-opportunistic-unconstitutional-assault-on-cryptocurrency-self-custody-developers-and-node-operators/) It's a proposterous violation of the U.S. 1st Amendamnt and a sign that the attack on self custodial bitcoin is here (https://twitter.com/LynAldenContact/status/1603084941608341509) The mainstream coverage of this unsophisticated attack on bitcoin is similarily uncritical and myopic (https://www.cnn.com/2022/12/14/business/elizabeth-warren-bipartisan-crypto-crackdown/index.html) Lyn's right that fundamental fights about property rights (https://twitter.com/LynAldenContact/status/1603084959769661440?cxt=HHwWgMC8veDRpr8sAAAA) are coming Economics US Government interest on debt accelerating (https://twitter.com/charliebilello/status/1602445402657226752) per Lyn Alden's model of a government debt spiral Privacy Know Your Customer (KYC) and Anti-Money Laundering (AML) rules are, according to research (https://www.coindesk.com/layer2/sinweek/2022/08/31/the-perverse-impacts-of-the-anti-money-laundering-system/), an exercise in bureacratic 'ass covering' and do nothing to promote lawful economic activity or fair use of the financial system Bitcoin Education How does an etherium multisig (https://blog.keys.casa/how-casas-ethereum-wallet-works/) work? And what this tells us about bitcoin Bitcoin Optech Newsletter #230 (https://bitcoinops.org/en/newsletters/2022/12/14/) has some cool links Feedback Remember to get in touch bitcoindadpod@protonmail.com or @bitcoindadpod (https://mobile.twitter.com/bitcoindadpod) on twitter Consider joining the matrix channel (https://matrix.to/#/#bitcoin:jupiterbroadcasting.com) using a matrix client like element (https://element.io/get-started), details here (https://www.jupiterbroadcasting.com/community/matrix/) Listener Links Ruling for rulers (https://www.youtube.com/watch?v=rStL7niR7gs), a video Value for Value Podcasting 2.0 to support an indepenent podcasting ecosystem (https://podcastindex.org/) Recomended Podcasting2.0 apps: Fountain (https://www.fountain.fm/) podcast app (Android) Podverse (https://podverse.fm/) (Cross platform and self hostable) Castamatic (https://apps.apple.com/us/app/castamatic-podcast-player/id966632553) (Apple)+ Podcasting 2.0 to support an indepenent podcasting ecosystem (https://podcastindex.org/) Send a Boost via the Podcast Index web page. No Podcast app upgrade required. + Install Alby (https://getalby.com/) + Find the Bitcoin Dad Pod on the Podcast Index (https://podcastindex.org/podcast/5049889) + Boost right from the page! Sponsors and Acknowledgements Music by Lesfm from Pixabay Self Hosted Show (https://selfhosted.show/) courtesy of Jupiter Broadcasting (https://www.jupiterbroadcasting.com/)

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Harry Paul Erba, MD, PhD Guest: Uma Borate, MD, MS With the development of technologies paired with an enhanced understanding of the AML genomic landscape, it's become possible to further the development of AML therapies. Joining Dr. Charles Turck to explore venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.

Guest: Ilene Galinsky BSN,MSN,ANP-C Patients with acute myeloid leukemia (AML) are at high risk for febrile neutropenia or profound, protracted neutropenia. So how can we monitor for the risk of neutropenia in AML patients starting venetoclax therapy? That's what Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute, is here to explain.

JAC… the Future Stars Champion of AML… trained in part by Beer City Bruiser and a former MMA fighter. We talk about the transition from MMA to pro wrestling and various other aspects of his career so far. Be sure to follow him and his fiancé another fellow AML roster member at the links below.. Twitter: JACisabadman, clarawrestling Instagram: jacisabadman, clarawrestling Tik tok: clarawrestling #prowrestling #independentwrestling #AML #wwe #ringofhonor #aew #gcw #impactwrestling #letsfngo #drinkinatmos --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/drinkinatmos/message

Today's blockchain and cryptocurrency news Bitcoin is down slightly at $17,689 Ethereum is down .5% at $1,286 Binance Coin is down .5% at $264 FTX lawyers ask judge to restrict Bahamian access Senator's Warren and Marshall introduce AML crypto bill Gemini said phishing attack nabbed some customer information Microsoft updates TOS to prohibit crypto mining. Cathie Wood + ARK buy more COIN. Learn more about your ad choices. Visit megaphone.fm/adchoices

In the final installment of our investigative journalism miniseries, host Alex Pillow is joined by The Sentry's Michelle Kendler-Kretsch, Investigative Coordinator and Data Specialist, and Debra LaPrevotte, Senior Investigator and former FBI supervisory special agent. Their engaging, dynamic conversation drives home how investigative journalism plays a critical role in the anti-financial crime ecosystem. A few of the many highlights include:How deeply concentrated insight from investigative journalists strengthen due diligence processes in the private sectorWhat signs to look for when assessing shell companiesWhy data transparency is paramount for an AFC network to defeat bad actorsVisit The Sentry's website to learn about the work it is doing to defeat predatory networks. You will find all their reports, including the recent report Michelle mentions, Constructing Corruption: Identifying the Enablers Helping Build Violent Kleptocracies.Additional resources about investigative journalism include the International Consortium of Investigative Journalists (ICIJ) and the Organized Crime and Corruption Reporting Project (OCCRP).

Jermaine Reid of Georgia was playing a recreational basketball game when, all of a sudden, he couldn't catch his breath.   Jermaine had not been to the doctor in quite some time and he knew something was wrong.Next thing you know, he was in the Bone Marrow Transplant Unit at Northside Hospital, unable to be around his children.  He was fighting with acute myeloid leukemia.   But it was a chance meeting with another patient on his second day that completely changed his perspective.   All of a sudden he heard a voice tell him, "This is Your Assignment."  Jermaine takes us through his battle with AML, his newfound friendship with a fellow patient, and how at every step of the way, his faith sustained him.  He cites several Bible verses which rang especially true for him in his time of need.Jermaine gives us several great pieces of advice for fellow patients, including keeping perspective and goals in mind - and not getting hung up on the numbers.  And he also talks about how important a made bed can be.We close by talking about our guest's continued advocacy in this space, including a recent speaking engagement at Northside Hospital and going to college campuses.  ResourcesDKMS, https://dkms.orgBe The Match, https://bethematch.orgNational Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page:  https://www.facebook.com/nbmtLINKnbmtLINK YouTube Page can be found by clicking here.Thank you to this season's sponsors:The Leukemia & Lymphoma Society, www.lls.orgSanofi: https://www.sanofi.com/ 

https://www.dropbox.com/s/12eceygkzzspiif/Gregory%20Dellas.mp3?dl=0   In today's episode of the Future of KYC Compliance, Ian is joined by Gregory Dellas, Chief Compliance and Innovation Officer at ECOMMBX. Gregory highlights the importance of staying current with regulatory changes, being one step ahead of criminals, and properly utilizing technology in the  fight against financial crime.   Gregory, founder and Chair of the ACAMS Cyprus Chapter, is a certified CAMS and GCI certified trainer, a Fellow of the International Compliance Association and a long-standing member of the Anti-Money Laundering Professionals Forum. He shares how these organizations enabled him to  join forces with fellow anti-financial crime professionals to achieve efficient and effective KYC and AML compliance.   Topics discussed: What drew Gregory  to a career in AML and  fighting financial crime The reasons why organizations fail to implement successful AML programs AML and financial crime related risks Gregory has seen emerge in the recent years  The common reporting mistakes that are now starting to occur because of the shift in  the way we  engage  with clients  Trends Gregory has seen AML professionals have used to try and remove data error points The primary challenges  faced by  frontline compliance teams and institutions The importance of having the right culture within an institution in KYC compliance Advantages of joining AML organizations Key pillars that underpin an effective AML compliance program  Gregory's advice  for professionals to win the battle against financial crime

Ram Ahluwalia, CEO and cofounder of crypto-native investment advisor Lumida, and Marc Cohodes, individual investor and former hedge fund manager, have a heated debate about Silvergate, a crypto-friendly bank that plays a key role in integrating crypto with traditional finance and is currently under scrutiny due to its ties with FTX and Alameda. Both Marc and Ram have a vested interest in Silvergate. Marc is shorting the stock, while Ram is longing it.   Show highlights: why Silvergate plays such a vital role in the movement of money within the crypto industry whether Silvergate runs proper KYC and AML practices whether Silvergate has a $1 billion hole in its balance sheet whether regulators will go after Silvergate as they are doing with FTX why Marc thinks the FTX collapse wouldn't have happened without Silvergate  whether Silvergate was complicit with FTX's activities or simply negligent  why Ram believes this case is different from JPMorgan's involvement with Madoff  what regulatory actions might come in the near future for Silvergate  why Ram thinks regulators will go to "great lengths" to avoid a bank failure what would it take for Ram and Marc to change their minds   Take Unchained's 2022 survey!   Unchained is doing its annual survey. Tell us how you think we're doing and how we could improve, whether it be on the podcast, in the newsletter, or in our premium offering. Looking forward to hearing your thoughts!  Thank you to our sponsors! Crypto.com Chainalysis Minima DeFi Saver  Guests: Ram: Twitter Ram's thread on Silvergate Ram's previous appearances on Unchained: Genesis May Be Facing Bankruptcy. Could It Take DCG Down With It? Why Genesis Could Very Well Be Insolvent, Not Just Illiquid Marc: Twitter   Episode links: Class action lawsuit against Silvergate The Block: Silvergate CEO seeks to reassure investors over crypto contagion Letter from Senators Elizabeth Warren, John Kennedy, and Roger Marshall The Guardian: JP Morgan Chase to pay more than $2bn in penalties for Madoff ties The Financial Times: Silvergate: from tiny local lender to bank behind the crypto boom WSJ: Crypto Is Taking a Few Small Banks on a Wild Ride Bloomberg:  These Banks Were Left Holding the Bag in Crypto Implosion An Obscure Bank Found Its Key to Success. Then FTX Collapsed CoinDesk: Crypto Bank Silvergate Says Its BlockFi Digital-Asset Deposit Exposure Totals Less Than $20M New York Post: Crypto ‘smart' money? Big traders fell for Sam Bankman-Fried NBC: Sen. Warren demands answers from Silvergate Bank about its business dealings with FTX Dylan LeClair's Twitter thread Learn more about your ad choices. Visit megaphone.fm/adchoices

As the year comes to a close, leading SRA consultancy service, Compliance Office, look at the latest SRA compliance developments and hot topics for law firms. Founder Andy Donovan speaks to leading regulatory solicitors Julie Norris and Iain Miller at Kingsley Napley and Ruth Mittlemann Cohen, an AML product specialist at VinciWorks. They look at: What the SRA's increases in fining powers mean in practice Christmas parties and appropriate behaviour Social media and other professional comms blunders SRA's new expectations around office culture Hot off the press analysis of the SRA's new guidance on supervising fee earners which will prove to be a hot topic! SLAPPs and new guidance on using 'confidential' & 'without prejudice' labels Corporate undertakings - where are we now? A look ahead to the hot topics in 2023 - AML (brief update only as that is its own session!), Legal Ombudsman time limit changes, forthcoming thematic review & more Speak to Compliance Office today: https://complianceoffice.co.uk/contact/

Last week, senior editor Annalee Armstrong and staff writer Gabrielle Mason covered the Clinical Trials on Alzheimer's Disease conference. We'll hear from them as they discuss the latest news and what surprised them.   Also in this episode, we cover the week's biggest headlines including an investigation into Neuralink, Google's DeepMind and why things aren't working out for PI3Ks. To learn more about topics in this episode: Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal Facing a familiar side effect problem, Eisai makes the case for its next Alzheimer's drug after patient deaths Roche thins Alzheimer's program after phase 3 failure, may seek 'external partnerships' A winner is crowned in head-to-head Alzheimer's battle between Biogen's Aduhelm and Lilly Neuralink under federal investigation for animal testing practices: Reuters Elon Musk claims Neuralink is 6 months from implanting brain-computer interfaces in humans—and, someday, he'll be one of them 'Troubling' study finds Google's kidney disease-predicting AI performs worse in women—and may not have a quick fix In fresh blow to floundering PI3K space, FDA feedback drives MEI, Kyowa to halt blood cancer program Rigel scores green light in AML just 4 months after buying asset from Forma UPDATED: J&J bows out of Horizon bid as Amgen and Sanofi eye cash plays for rare disease drugmaker Pfizer plots €1.2B investment—and up to 500 new jobs—at Irish manufacturing plant Fierce JPM Week "The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

Tumor-Infiltrating Lymphocytes (TILs) getting closer to entering practice. Updated survival results published from DESTINY-Breast03 (T-DXd vs. T-DM1). A new IDH1 inhibitor, olutasidenib, is FDA-approved for relapsed or refractory AML.

In the next installment of ASTCT's Titans of Transplant series, Susan Slater, nurse practitioner and recipient of the Best APP Abstract Award at the 2016 BMT Tandem meetings and the 2020 APP SIG Lifetime Achievement Award, is interviewed by Dr. Jennifer Saultz, Assistant Professor of Medicine at Oregon Healthy & Science University and a member of the Adult Transplant and cellular therapy team. About Susan Slater Susan Slater, MN, FNP-BC is an Assistant Professor of Medicine in the Knight Cancer Institute at Oregon Health & Science University. She has 25 years' experience as nurse practitioner caring for patients with hematologic malignancies undergoing stem cell transplantation. Her main focus of care is long-term follow up and survivorship care. She's the recipient of the Best APP Abstract Award at the 2016 BMT Tandem meetings as well as the 2020 APP SIG Lifetime Achievement Award. She is the co-editor of Blood and Marrow Transplant Handbook which is currently in its third edition. She also serves as the Co-director of the Knight Cancer Institute APP Fellowship Program and looks forward to enrolling the first cohort of fellows in January, 2023. About Jennifer Saultz Dr. Jennifer Saultz (@jennifernsaultz) is an Assistant Professor of Medicine at Oregon Healthy & Science University and a member of the Adult Transplant and cellular therapy team. Her research focuses on the innate immune resistance signatures in AML. She is also a member of the ASTCT Content Committee. The Titans of Transplant series seeks to recognize, celebrate and chronicle the physicians, researchers, pharmacists, nurses, social workers and more who were on the frontlines of the early days of transplant.

Featuring perspectives from Dr Daniel Pollyea, including the following topics: Introduction (0:00) Acute Myeloid Leukemia (AML), 2014 to 2022 (3:35) Defining AML versus Myelodysplastic Syndromes (6:06) Case: A man in his early 80s presenting with cytopenias and AML (8:56) Oral Decitabine/Cedazuridine (18:15) Management of Cytopenias with HMA (Hypomethylating Agent)/Venetoclax: Drug-Drug Interactions (26:43) HMA/Venetoclax for Younger Patients (39:56) Translational Biology of AML: New Agents and Treatment Strategies (44:08) Case: A man in his mid 70s with p53-mutated AML and complex karyotype (47:48) Anti-CD47 Antibody Magrolimab (51:08) Case: A woman in her early 60s with MLL-rearranged AML after receiving 7 + 3, FLAG-IDA and azacitidine/venetoclax (54:22) CME information and select publications

Here are the links for everything discussed in Episode 87. Times are also below so feel free to skip around and get to the updates that interest you.  (1:08) Approval of Hemgenix for Hemophilia B (4:45) Rebyota approved for recurrence of CDiff infection (9:39) New approval for AML with IDH1 mutation - Rezlidhia CDC website for COVID information - get boosted!FDA monkeypox response websiteConnect with The Rx Daily Dose:Twitter      Instagram      YouTube      Linkedin       WebsiteEmail: therxdailydose@gmail.comConnect with Ian Parnigoni PharmD. on social media:Twitter       Instagram       Linkedin  ★ Support this podcast on Patreon ★

In this episode of the Principled Podcast, host Susan Divers continues her conversation from Episode 11 with Tom Fox, the founder of the Compliance Podcast Network, on the changing geopolitical landscape and its impact on E&C. Listen in as the two discuss how anti-corruption is a key component of ESG, the consequences of compliance in cybersecurity, and the growing interconnectedness of risks. You can listen to Episode 11 here.  To learn more, download a copy of Tom Fox's white paper Never the Same: Five Key Areas in Which Business Will Never Be the Same After the Russian Invasion.    Featured guest: Tom Fox Tom Fox is literally the guy who wrote the book on compliance with the international compliance best-seller The Compliance Handbook, 3rd edition, which was released by LexisNexis in May 2022. Tom has authored 23 other books on business leadership, compliance and ethics, and corporate governance, including the international best-sellers Lessons Learned on Compliance and Ethics and Best Practices Under the FCPA and Bribery Act, as well as his award-winning series "Fox on Compliance." Tom leads the social media discussion on compliance with his award-winning blog, and is the Voice of Compliance, having founded the award-winning Compliance Podcast Network and hosting or producing multiple award-winning podcasts. He is an executive leader at the C-Suite Network, the world's most trusted network of C-Suite leaders. He can be reached at tfox@tfoxlaw.com.   Featured host: Susan Divers Susan Divers is the director of thought leadership and best practices with LRN Corporation. She brings 30+ years' accomplishments and experience in the ethics and compliance arena to LRN clients and colleagues. This expertise includes building state-of-the-art compliance programs infused with values, designing user-friendly means of engaging and informing employees, fostering an embedded culture of compliance, and sharing substantial subject matter expertise in anti-corruption, export controls, sanctions, and other key areas of compliance. Prior to joining LRN, Mrs. Divers served as AECOM's Assistant General for Global Ethics & Compliance and Chief Ethics & Compliance Officer. Under her leadership, AECOM's ethics and compliance program garnered six external awards in recognition of its effectiveness and Mrs. Divers' thought leadership in the ethics field. In 2011, Mrs. Divers received the AECOM CEO Award of Excellence, which recognized her work in advancing the company's ethics and compliance program. Before joining AECOM, she worked at SAIC and Lockheed Martin in the international compliance area. Prior to that, she was a partner with the DC office of Sonnenschein, Nath & Rosenthal. She also spent four years in London and is qualified as a Solicitor to the High Court of England and Wales, practicing in the international arena with the law firms of Theodore Goddard & Co. and Herbert Smith & Co. She also served as an attorney in the Office of the Legal Advisor at the Department of State and was a member of the U.S. delegation to the UN working on the first anti-corruption multilateral treaty initiative.  Mrs. Divers is a member of the DC Bar and a graduate of Trinity College, Washington D.C. and of the National Law Center of George Washington University. In 2011, 2012, 2013 and 2014 Ethisphere Magazine listed her as one the “Attorneys Who Matter” in the ethics & compliance area. She is a member of the Advisory Boards of the Rutgers University Center for Ethical Behavior and served as a member of the Board of Directors for the Institute for Practical Training from 2005-2008. She resides in Northern Virginia and is a frequent speaker, writer and commentator on ethics and compliance topics.  Principled Podcast Transcript Intro: Welcome to the Principled Podcast, brought to you by LRN. The Principled Podcast brings together the collective wisdom on ethics, business and compliance, transformative stories of leadership, and inspiring workplace culture. Listen in to discover valuable strategies from our community of business leaders and workplace change makers. Susan Divers: Hello and welcome to another episode of LRN's Principled Podcast. I'm your host, Susan Divers, Director of Thought Leadership and Best Practices at LRN. Today, I'm continuing my conversation from episode 11 with Tom Fox on the changing geopolitical landscape and its impact on ethics and compliance. If you haven't listened to that episode yet, we highly encourage you to do so. Tom is the founder of the Compliance Podcast Network and the author of the award-Winning FCPA Compliance and Ethics Blog, as well as the Complete Compliance Handbook, which is in its third edition. Tom, welcome back to Principled Podcast. Tom Fox: Thank you, Susan. Susan Divers: Tom, in our last episode, we talked about the impact of the war in the Ukraine on compliance and ethics. And specifically on the challenges that's imposed or brought to the fore for companies and specifically for their compliance teams who hopefully have a real seat at the table in terms of dealing with those challenges and mitigating those risks. But one of the topics that underlies what we were talking about is that of conducting your business in a fair, transparent, and sustainable manner. And I'm really struck by some of the things you were saying about the need to be transparent and the need to walk the walk and talk the talk. Because if you fail to do so, we live in an age of radical transparency and easy access to social media, and moreover, it's the right thing to do. So with that as the background, anti-corruption has long been a focus for regulators. I mean, it's probably defined yours and my careers in a lot of regards. But only recently have some people started talking about it, and you're one and I'm one, as a major component of ESG. Could you explain for our listeners how that works and the role of anti-corruption in ESG? Tom Fox: Sure. So ESG, in my mind, Susan, the power of ESG is that it has brought together disparate strands that have existed in every corporation for some lengthy period of time. But brought them together in a way that someone is looking at them holistically. So, I'll pick on E because that perhaps is the easiest. As a compliance officer, I never looked at environmental issues in our company. That was somebody else's responsibility. Susan Divers: Me either. Right. Tom Fox: Didn't mean there wasn't environmental compliance, but it meant that I wasn't looking at that from the compliance perspective. Now, whether it's the Chief Sustainability Officer, whether it's the Board of Directors, whether there's a Board ESG Committee, somebody's connecting compliance to environmental. And so that in and of itself is, to me, the most powerful reason to have a robust ESG program. But anti-corruption in ESG, in my opinion, Susan, I've always seen it directly in the G. Susan Divers: Me too. Tom Fox: Number one, it's a good governance issue. Number two, it is a Board of Director's issue. Number three, it's illegal and regulatory issue. But now Susan, I'm beginning to see it and have tried to articulate, that I see it in the S component as well as sustainability. Part of it is around one of the topics we touched on our last podcast of radical transparency, that if you do business ethically and in compliance, and if there's a question raised about a supplier, a customer, a distributor, a someone you've done business with in today's era of modern social media, that you can respond to that in a way that won't hurt your business from the public perception perspective. Leaving completely aside the regulatory perspective. So, I see ABC or anti-corruption compliance now, Susan, as directly within the S of ESG as well. And I also see it in the E. So to me, it sort of bleeds across all aspects of ESG and is a key component of a best practices ESG program. Susan Divers: Yeah, and I'm glad you articulated it so clearly for people, because I think there's a tendency perhaps, to silo ethics and compliance and sustainability. And they really are part and parcel of the same thing. And I'm going to quote from your recent white paper in support of that. "As a fundamental threat to the rule of law, corruption hollows out institutions, corrodes public trust, and fuels popular cynicism towards effective accountable governance." And that's, I think, a quote from the U.S. Strategy on Countering Corruption. Can you talk for us and link together how anti-corruption, anti-money laundering, and sanctions all are part and parcel of the same thing and relate to ESG? I think that'd be helpful for our listeners? Tom Fox: So Susan, the statement you read interests me for a couple of reasons. That came out of the U.S. Strategy on Countering Corruption, and it was aimed at national governments, so national governance. And I think it's absolutely correct that corruption, money laundering, all fuel cynicisms towards effective, accountable national governance. But Susan, as you were reading that, it struck me, that is equally true about corporate governance, or the G in ESG. Because violations of the rule of law, corruption, money laundering, they all corroded trust in our corporations, and indeed fuel cynicism towards effective accountable corporate governance. The United Nations estimates that $3 trillion is lost to the global economy annually because of bribery and corruption. The United States Department of Treasury estimates that $2 trillion is lost annually because of money laundry. That's $5 trillion taken out of the global economy that could be used for a wide variety of other ways, reasons to help countries and people that's not available to them. So having an effective anti-corruption and anti-money laundering strategy as well as trade sanctions, I think, are directly a part of ESG. They're certainly all in the G. We've talked about how they relate to sustainability. But money laundering and trade sanctions are as invidious, in my mind, as corruption is. After 9/11, we saw a spike in the first real spike in FCPA cases starting sort of circa '04. And it was said that corruption led to crime, which led to terrorism. And there was really a belief that corruption had a direct line to the terrorism that impacted the United States directly on 9/11. And now we see how corruption leads to erosion of trust in governance. But governance is not just corporate governance, it's democratic governance and democratic institutions. And certainly the Russian invasion of Ukraine put another exclamation mark on that. Whatever Russia is, it's not a democracy. And it is, if you want to see evidence of the invidiousness of corruption, you only need to look at a Russian army, their failures in Ukraine, how they've treated the people of Ukraine all wrapped up in an anti-democratic form. And that all speaks to the G. And when you read that line or that quote from my white paper, it struck me, that really works on multiple levels of governance. Susan Divers: Well, and you raise a good point too, that it's in the corporate governance area because if you... I've said this so many times, but it's worth repeating. If you have a code of conduct and you have training and you have policies, and you have an E&C team, that doesn't mean you have an ethical company, particularly if your leadership is engaging in sexual harassment or they're dealing with people who are banned because they're under sanction or they're violating anti-money laundering controls because it's a big account and they want the commission. That just means that your program is basically window dressing. So for corporations and for E&C professionals, it seems to me that making sure that you're doing business in an ethical, compliant way is part of and parcel of being sustainable. And part of demonstrating that trust that is essential, if you're going to do business effectively, as we've talked about. We talked last time a little bit about how the Biden administration has basically shifted the view of anti-corruption enforcement. And I think that bears reemphasizing, 'cause I thought that was such an interesting point that you raised about that in the last podcast. Do you mind repeating that? Tom Fox: Sure. So in December, 2021, the Biden administration release our U.S. Strategy on Countering Corruption. Once again, this did not come about because of the Russian invasion of Ukraine, but it occurred during the run up to it. And it's one of the things that I think the Russian invasion have put an exclamation point on as to why business will never be the same in certain areas. You and I have been in the anti-corruption field for a long time. As of December, 2021, our fight is now a national security fight. And they elevated anti-corruption and the fight against corruption to a national security issue. When something becomes a national security issue of the United States, that means resources are made available for that fight. The strategy released by the Biden administration was the internal U.S. Government Strategy. It didn't impact our former employers or us today directly. But what it did was say, "The U.S. is going to enhance the global fight against corruption. They're going to work with foreign partners, foreign prosecutors, foreign departments of justice or ministries of justice to bring to justice people who engage in bribery and corruption, people engage in money laundering in a way they haven't done before." Interestingly, there was a section on journalists and the fourth state and a specific acknowledgement that exposes, business exposes by journalists all the way from blood money of the story of Theranos to the Paradise Papers, to the Panama Papers, to the Paradise Papers, all exposed bribery and corruption, all exposed money laundering, all exposed sham corporations, all exposed fraud. And for the first time, we have the U.S. Government saying, "We're going to work to try to encourage good journalism to help expose these, because we can't do all of this on our own." And newspapers have a vital role to play, and reporters have a vital role to play. So, we have the fourth estate now being openly discussed by the United States. We have government agencies that had never concerned themselves with anti-corruption, now being tasked with anti corruption. And I would point you to NATO. NATO's been around most of our lives. No, well, I guess all of our lives. Susan Divers: Yeah. Tom Fox: It's a key component of what I see as U.S. Security interests. But I've never heard NATO and anti-corruption in the same breath before. Well, now NATO is charged with enforcing anti-corruption statutes for its suppliers. It's suppliers are not all U.S. companies. NATO's a 23 member, I think, organization. So any country can have suppliers to NATO. Well, now they have to comply with U.S. anti-corruption laws probably in the form of the FCPA. So, we have a greater scope, a greater reach, we have greater resources in the form of prosecutors or investigators. But the U.S. is acknowledging and saying, "This is part of our overall fight." And in part one of our episodes, Susan and I talked about the Department of Treasury saying that U.S. corporations are a part of the fight against money laundering. Well, I think the Department of Justice has come pretty close to saying that U.S. corporations are a part of the fight against bribery and corruption. And because it's a national security issue, we want you to come to us. We will incentivize you to come in and self-disclose, once again, even if it's within your organization. I think that this means more funds, a wider remit for government agencies that have not had this remit before. And when you start talking about the press as a key part or a key whistleblower within the context of overall whistle blowing programs, I think that's an acknowledgement that is long overdue. Susan Divers: I totally agree with you. And I think it also sort of ups the ante, because when you couple that with DOJ's recent re-emphasis and added emphasis on personal responsibility and liability for misconduct, it's in a sense saying, "If you go out and you bribe or you violate anti-money laundering or you do business with people on the sanctioned list, or you help oligarchs move their yachts, you're not just committing an economic crime. You're doing something that violates the U.S. National Security interests." And I think that's something for boards and executives to really think about, especially in light of the recent absolutely horrible Lafarge cement case where they were bribing ISIS in order to keep their Syrian cement factory open. It's an interesting dynamic. Let's leave that and let's talk about cybersecurity, because that's another major risk area for companies. And it directly plays into the area of sanctions in AML as well as others. What are you seeing in that space as a result of the war in the Ukraine and the risks that's created? Tom Fox: So once again, Susan, cybersecurity, cyber attacks, cyber hacks have been with us for some period of time. I think Target was probably the first one that got the attention of most of us in the compliance community. But certainly within the cyber community, this was well known. But what the Russian invasion of Ukraine has done is, here I have to cite to Brandon Daniels, CEO of Exiger who said, "We are now under permanent non-kinetic warfare.", meaning we are permanently under attack by our enemies in the cyberspace. Every company is subject to attack. It can be a state actor or it could be rogue groups. It could be criminal groups. So, that's sort of point one. We are all under attack now and we have to harden our defenses. But point number two is that what you sort of raise at the end, Susan, you're attacked, you're hacked. You want to get the key so you can unlock your documents. You make a payment. Who are you making that payment to? They're probably not going to say, "My name is Thomas Robert Fox. My bank account at Chase is..." They're going to give you a false name and some sort of drop account that you don't know, or you may not know who the end user is. Well, in 18 months or 24 months, when you get a little knock at the door from the Department of Treasury, which says, "You've just paid ISIS." Or, "You've just paid Russia. We'd like to ask you some questions under oath." The point being that if you don't know who you're paying, you may be paying someone who's on the sanctions list. You may be paying rogue agents or agents rather from Cuba, from North Korea. You may be paying agents from China. And so, cybersecurity is tied to money laundering and trade sanctions because of the potential payments. As a business, you're in an extraordinarily difficult position because you may have not had hardened defenses. And you may be at risk for losing your data or having it put out on the dark web. And that's not going to be an easy choice. But if you make a payment and it's to someone on the sanction list, the U.S. government has made clear, you will be punished for violations of those U.S. laws. And this fall, it's not effective yet, effective March, 2023, Lloyd's of London has announced that they will not honor cyber insurance obligations where the attack was made by a state actor. And typically what companies will do after they're hacked and they have to announce publicly is, they will say, "Well, we were a hacked by the Russian government and there's nothing we can do for it because it was a top military hacking unit in Russia. And whatever defenses we had in place, we couldn't defend us." Well, if you say that trying to cover your backside, you've just lost your insurance coverage. And if you make payments, you're not going to be able to get indemnity and that money back. So, you have to be very careful about what you publicly say now, if you want to have full cyber insurance. It's, here I'm less certain about the answer, Susan. I just know that the questions have become much more important, much more difficult. But you've got to have these conversations in your corporation. You've got to practice hack drill. It's like you and I did fire drills or bomb drills in elementary school. You've got to have a drill, you've got to have a plan in place. You've got to be ready, if you're hacked. You've got to have experts who you can call, trusted advisors, whether they be legal, whether it be technical, whether they be compliance, whether they be cyber, to come in and help you get through such an attack. But we're under... make no illusions that this Russian invasion has unleashed corporate attacks in a way we have never seen before. It's here to stay. And you as a U.S. corporation and U.S. compliance practitioner are going to have to deal with it. Susan Divers: Well, and what you're saying too is a perfect illustration of the interconnectedness, which I don't think we thought in those terms too much in the past. We had FCPA compliance and we had sanctions compliance and trade compliance and AML. We didn't really, at least, I didn't, to confess, sort of think about it as all connected. But if you're basically being held to ransom and it's a Russian or an ISIS hacker, then not only could you violate the sanctions laws, but you could violate anti-bribery laws too, inadvertently. To use a great expression, it's sort of a dog's breakfast in some ways, what compliance officers are faced with. So, what's your advice, because it's a new risk environment and the risks are really big? They're national security risks, they're not just good governance and good business risks. What should compliance officers do? Let's end on a practical note of, how do you actually deal with the situation going forward? Tom Fox: No, I wonder if I should open my door, bring my three dogs back in, and say, "Hey guys, what do you do when I put a dog's breakfast down in front of you?" And they look up at me and say, "Well, we eat it, Tom." It's here to stay. And that means you have to deal with it. It all goes back to risk. What are your risks? Assess your risks. Yes, I understand you have a robust cyber defense protocol. You have a program, you have tested that program, you've run drills on that program. Now, have you done that same with your prime supplier? Have you done that with your Tom Fox vendor who has access to the vendor invoice system so that I can input my invoice into your system for work I do? Have you checked down to that level to make sure that my defenses are hardened, someone using my system can't get in? You have to go through the same exercise you do from a corruption compliance, any money laundering compliance, trade control, and trade sanction compliance. Assess your risk. How do you assess your risk? Where are you doing business? Who are you doing business with? How are you doing business? In all of those manners, are there any gaps in your defenses in those three areas? If you assess those risks and then if you find gaps, weaknesses, material deficiencies, whatever you choose to call them, remediate those. It is a process you have to go through. You can't do it... I'm going to look at our cyber defenses in our third party supply chain this afternoon. You can't do that. It is a process and you're going to have to put work into it. But that's where you get the real results. Because once again, as we found, I think in the supply chain discussion we had, Susan, once you look at those sub-suppliers, who you're doing business with, where they're doing business, and how you're doing business, you may find inefficiencies from the business operations perspective. And you can correct or improve those business efficiencies and make your company more efficient, and hopefully at the end of the day, more profitable, when you began as a program to assess risk based upon a DOJ pronouncement or a DOT pronouncement. But it all starts with recognizing what your risks are. And only you can assess your risks. Susan Divers: And I like too, the way you've mapped it out, because it really, again, comes full circle back to sustainability, that the way you do business is just as important as what business you do. And if you truly keep on top of your risks and really reinvigorate the risk function, that should be, as you've pointed out, a dialogue with the board and with the top management. It shouldn't be a dialogue that compliance and audit and legal are having because it involves the strategic direction of the company. And it also involves the way the company is governed. So with that takeaway, I think this is a conversation we could be having for at least another hour, if not more. But we're out of time. And so Tom, thank you so much for joining us. And your thoughts are so valuable, because I think it's easy in the ethics and compliance field to get fixated on, "How am my rolling out the training? What's my curriculum, how many hotline calls have I gotten?" And it's much more about, how do we actually live in this world? And how do we in fact, conduct business in a way that's ethical, compliant, and sustainable? So you've really taken us to that perspective. And I'm very grateful to you for doing that. Tom Fox: Susan, thank you, and I look forward to continuing this conversation. Susan Divers: Thank you, Tom. My name is Susan Divers and I want to thank you all for tuning into the Principled Podcast at LRN. Outro: We hope you enjoyed this episode. The Principled Podcast is brought to you by LRN. At LRN, our mission is to inspire principled performance in global organizations by helping them foster winning ethical cultures rooted in sustainable values. Please visit us at lrn.com to learn more. And if you enjoyed this episode, subscribe to our podcast on Apple Podcasts, Stitcher, Google Podcast, or wherever you listen. And don't forget to leave us a review.    

In this episode, cryptocurrency expert Matt Stankiewicz discusses why sanctions and AML compliance need to be taken seriously in the cryptocurrency industry.Matt Stankiewicz, a Partner at Volkov Law, is a leading industry expert on cryptocurrency. Bittrex, a leading cryptocurrency exchange, suffered twin enforcement actions for AML and Sanctions Compliance deficiencies. Matt takes a deep dive on the enforcement actions and outlines practical compliance steps that every cryptocurrency exchange should implement.Join us as we discuss:The enforcement action on Bittrex led by OFAC and FinCENWhy compliance risks are increasing in the cryptocurrency industryPractical steps that all cryptocurrency exchanges should implement To reach Matt email him at: mstankiewicz@volkovlaw.com

Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Donna: Hi Dr Cabral! I was recently diagnosed with a renal AML of 1.3cms and focal nodular neoplasm on my liver was noticed on my ultrasound. I need to now do an MRI to further investigate. I can't find any archived podcasts on these issues. Some background info: I was on “Yas” birth control pill for 8 years from 14-22 years old, and in the last 2 years I took antibiotics 8 times for UTIs. I'm someone who normally NEVER takes medication. I eat well, don't drink or smoke, but I've undergone a lot of stress since becoming a mom 4 years ago and feel like it's been since that time that my health has started to deteriorate as I try to juggle motherhood with running my own growing business. I'll be running the big 5 labs in 2 weeks, as I'm convinced they will shed more light on my health. Any input from you would help! Will these tumors ever go away in your experience? Thank you so much, I value your consideration and time!   Maria: Hi Dr Cabral! I would love to hear your thoughts on lecithin as a supplement. Do you recommend it? If so, how does it support the body and what benefits are there? I've heard it connected to cognitive functions, nerves, skin, cholesterol etc. Could it be helpful for someone who has signs of dementia? What about when there's loss of sensitivity, tingling and numbness in lower parts of the legs and feet? Or is there anyone is particular that is at risk of being low in lecithin? Many many thanks for all you do, your podcast is like my encyclopedia on all health related matters.   Jesseca: Hi Dr. Cabral, Thank you so much for all of the education you share. I've learned so much from you and am so grateful to have resources like yours to empower myself and my family to live happy, healthy lives. I have two separate questions that I asked in the Facebook support group, and they don't appear to have been answered before: 1) What is your opinion on chemical peels and products like retinol as part of a regular skin care routine? As I understand it, both make your skin very sensitive to the sun (requiring very diligent SPF application), which raises some red flags for me. What do you think? 2) What is your opinion on using mushrooms like lions mane, chaga, and cordyceps while pregnant? I'm planning on getting pregnant in the next year and am thinking about how to replace my morning coffee. When I've decided to give up caffeine in the past, I found mushrooms like this (e.g. FourSigmatic's functional creamer) to work really well as an alternative. I know you recommend reducing herbs while pregnant. Would mushrooms like this fall in the same category? Thank you! Jesseca   Tina: You are amazing, and thanks for all you do! My 13-year-old son was just diagnosed with severe swelling in his sinuses, a deviated septum, and sinus polyps. I have him on daily omegas, daily activated mullti, periodic balanced zinc, daily probiotic, 3 HistPro 2 X per day, and I just ordered the alkalizing vitamin c (all Equilife products). I was forced to start him on Flonase, but I also have him on the nutribiotic GSE nasal spray. They want to do surgery, but they agreed to see if his nose improved after three months on the Flonase. So, three questions: 1-How much alkalizing vitamin c should he take? 2- Is it fine to keep him on all of these other things, and for how long? 3-Is there anything else I could be doing before this follow-up visit to help him so that his nose improves and they don't want to push us into the surgery? He's just over 100 pounds and very fit and active. He has all of the seasonal allergies and allergies to peanuts, tree-nuts, and sesame. I know it will take a while for you to answer, and I did ask on Facebook as well, but I know this will be an ongoing issue, so I wanted to get your opinion since I really value it.   Jackie: My practitioner has recommended the Candida and Bacterial Optimizer (CBO) protocol. He is not an expert on Small Intestinal Bacterial Overgrowth, however. He has noted that my good bacteria diversity is really low. I have been on antibiotics and antimicrobials for 10 months to combat my SIBO. So far, no luck. My hydrogen level remains elevated. My question is this. Is this particular protocol good to disrupt established and tough biofilms? Or is this protocol better for someone who would be using this protocol as a first round against SIBO? Has it ever been used with success on SIBO patients who had tough biofilms to break down? Finally, is there a reason why EDTA is not included in the biofilm buster formula?   Ales: Hello Dr. Cabral, I have a question regarding earth probiotic strains like B.coagulus, B.clausii, B.subtilis. Lately, I have seen many products of these particular strains being used, especially in combination with botanicals and biofilm removers to help with SIBO. Is there any real evidence regarding soil based probiotics or you aren't convinced of their efficacy? With SIBO or in general?   Ales: Hello Dr. Cabral, in my last question I forgot to add that I work in a functional medicine clinic, where we analyse gut microbiom. We see very often low counts of akkermansia muciniphila, which is critical for healthy gut barrier. Soil based probiotics are suppose to indirectly increase akkermansia. Do you see any valuable evidence of that?   Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right!   - - - Show Notes and Resources: StephenCabral.com/2487 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!

Fetch your earbuds! It's time for a new episode of the pupcast—woof, we mean PODcast. But really, our dogs are barkin' and for once that isn't a euphemism for med-induced foot pain. No, we're talking a beautiful Mitzvah, here! Then, Amy gets a wicked case of stage fright as she MyChart dives into some scan results that send her into a panic with nary a disco in sight, while Stef recaps her wedding to that same old guy and her scan with the same old results. Mazel tov! A listener letter has the gals shaking their heads (and fists) at a funeral-goer's tactless question. Then, a pimple-prone cancer honey needs solutions for the problems popping up since starting cancer treatment. RATS has good news for AML patients whose telomeres are just a little Too $hort. Oy vey!Here are the AML articles we used for this RATS: https://www.mdanderson.org/cancerwise/acute-myeloid-leukemia-survivor-shows-no-signs-of-cancer-after-clinical-trial.h00-159538167.htmlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729630/Check us out on The Cancer Pod! https://podcasts.apple.com/us/podcast/amy-stef-cancer-for-breakfast-cancerinsider/id1584013388?i=1000585608993Here is that site that lets you search trials and check for drug and food/supplement interactions: https://metastatictrialtalk.org/Cancer for Breakfast is hosted by Amy Dials and Stefanie LeJeunesse, and is produced by Nathan McGehee.Our theme music is by Vyvyvyr. RATS theme song is by Jessica Boudreaux of Summer Cannibals. Want to support the podcast? We're on BuyMeACoffee and Patreon. We appreciate it so much when you rate, review or subscribe on Apple Podcasts,  you can do that RIGHT HERE!  e-mail us at cancerforbreakfast@gmail.com

Today's Squawk Pod is brought to you by the letters CZ, SBF, FTX … and BUSD? AML? There is, seemingly, no end to the many, many abbreviations, initials and vernacular related to the collapse of crypto exchange FTX and the aborted deal by the world's largest crypto exchange, Binance, to buy it out before bankruptcy.  Binance CEO Changpeng Zhao “CZ” slams the behavior of his one-time friend and professional rival, FTX's former leader Sam Bankman-Fried: “I'm just shocked.” CZ tells his behind-the-scenes story of Binance's due diligence into the books at FTX and decision to walk away from acquiring the platform. Squawk Box anchors Joe Kernen, Becky Quick and Andrew Ross Sorkin get into all the tweets, the tokens, the DMs, the PR stunts, and what's next for folks at places like the SEC and the DOJ.  Plus, the Republicans make a House majority official and Ticketmaster's Taylor Swift fiasco hits Swifties of all generations.  In this episode:CZ, @cz_binanceJoe Kernen, @JoeSquawkAndrew Ross Sorkin, @andrewrsorkinBecky Quick @BeckyQuickKatie Kramer, @Kramer_Katie

Featuring a slide presentation and related discussion from Dr Eytan Stein, including the following topics: Historical paradigms for treating newly diagnosed acute myeloid leukemia (AML) (0:00) Long-term findings and emerging results with venetoclax-based therapies for newly diagnosed and relapsed/refractory (R/R) AML (1:19) Efficacy and tolerability of oral decitabine/cedazuridine for patients with AML (19:27) Mechanism of action, activity and safety of magrolimab-based therapies for newly diagnosed and R/R disease (23:34) Sabatolimab: Mechanism of action and efficacy in combination with a hypomethylating agent (32:01) Therapeutic targeting of Menin and NPM1 mutations in AML; activity of entospletinib in combination with induction chemotherapy (37:29) CME information and select publications

Featuring an interview with Dr Eytan Stein, including the following topics: Practical considerations for using venetoclax/HMA (hypomethylating agent) combinations in the management of acute myeloid leukemia (AML) (0:00) Approach to transplant for older patients with AML (10:33) Potential availability of magrolimab and sabatolimab in clinical practice (13:04) ASH 2022 preview: Investigational therapies excluding transplantation and cellular immunotherapies (17:33) Activity, tolerability and future directions with FLT3 and IDH inhibitors in AML (22:29) CME information and select publications

There's nothing like having the opportunity to meet new people and spend quality railfanning time with friends. The Station Inn - https://stationinnpa.com/ - located along the Norfolk Southern mainline just west of Altoona is probably one of the best railfanning spots in all of North America. First opened in 1993, as the brainchild of Tom Davis a retired school administrator from New Jersey. Not long after it opened, an advertisement was placed in one of the more popular rail magazines of the day and a young “Uncle” Dave along with his brother and a couple of friends spent a weekend at “the Inn.” Dave's been coming back every year since with an ever-growing band of characters, this was the twenty-nineth straight year for Dave and the first for the AML crew. With microphone in hand the “Evel Overlord” decided to find out what's the deal with Dave through the eyes of his friends and brother Ben. It's a great interview that we know you'll enjoy!!!

In this show in association with LexisNexis Risk Solutions – our expert host, David M. Brear , is joined by some great guests to ask: “Is the future of AML and fighting financial crime about investing in people, or automation?” With the current climate of economic downturns, global conflict, and international sanctions - fighting financial crime has never been tougher. But is the answer better equipping humans to spot the signs of financial crime, or creating more sophisticated systems through machine learning? We discuss the current challenges, the role of orchestration, and more! This week's guests include: Eddie Vaughan, Sales Director, LexisNexis Risk Solutions Dan Argent, Head of Financial Crime and MLRO, GB Bank. Jessica Cath, Head of Financial Crime Project Delivery, FINTRAIL This episode is sponsored by LexisNexis Risk Solutions LexisNexis® Risk Solutions harnesses the power of data and advanced analytics to provide insights that help businesses and governmental entities reduce risk and improve decisions to benefit people around the globe. Leveraging automation and machine learning from the ground up, the LexisNexis® RiskNarrative™ platform, as recognised by Gartner, is a smart, configurable financial crime and fraud lifecycle management solution enabling businesses to seamlessly manage all customer journeys within a simple, no-code integration. For more infomation, visit risk.lexisnexis.co.uk (https://risk.lexisnexis.co.uk/) Fintech Insider by 11:FS is a podcast dedicated to all things fintech, banking, technology and financial services. It's hosted by a rotation of 11:FS experts including David M. Brear, Ross Gallagher, Benjamin Ensor, and Kate Moody - as well as a range of brilliant guests. We cover the latest global news, bring you interviews from industry experts or take a deep dive into subject matters such as APIs, AI or digital banking. If you enjoyed this episode, don't forget to subscribe and please leave a review Follow us on Twitter: @fintechinsiders where you can ask the hosts questions, or email podcasts@11fs.com! Special Guests: Dan Argent, Eddie Vaughan, and Jessica Cath.